RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Alessandra Vignola has joined Worldwide Clinical Trials (Worldwide), a global full-service contract research organization (CRO), as President of the Cardiovascular & Metabolic Business Unit. Vignola brings more than 30 years of extensive experience in the pharmaceutical and clinical research industry, enhancing the company's leadership in these critical therapeutic areas..

北卡罗来纳州三角研究园（商业新闻）——亚历桑德拉·维诺拉（AlessandraVignola）加入了全球临床试验（Worldwide），这是一家全球全方位服务合同研究组织（CRO），担任心血管与代谢业务部门的总裁。Vignola在制药和临床研究行业拥有30多年的丰富经验，增强了公司在这些关键治疗领域的领导地位。。

In this role, Vignola will oversee the Cardiovascular & Metabolic Business Unit, leading Worldwide’s therapeutically-focused team and partnering with sponsors to advance new medications through clinical development while driving business growth for Worldwide. Her appointment comes at a pivotal time for the cardiovascular and metabolic sectors, which are undergoing rapid advancements, particularly in the areas of diabetes and obesity, as well as across all cardiovascular-kidney-metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and other acute and chronic liver diseases..

在这个职位上，Vignola将监督心血管和代谢业务部门，领导全球以治疗为重点的团队，并与赞助商合作，通过临床开发推进新药，同时推动全球业务增长。。。

The escalating obesity epidemic is contributing to a surge in cardiovascular and metabolic comorbidities, including diabetes, liver disease, and other serious health conditions. As these interconnected health challenges become more prevalent, the need for effective treatment options is urgent. Research has expanded into various therapeutic approaches, including promising medications like GLP-1 (glucagon-like peptide-1) receptor agonists, initially developed for type 2 diabetes but now being explored for broader applications such as cardiovascular disease and obesity management.

不断升级的肥胖流行正在导致心血管和代谢合并症的激增，包括糖尿病，肝病和其他严重的健康状况。随着这些相互关联的健康挑战变得更加普遍，迫切需要有效的治疗选择。研究已经扩展到各种治疗方法，包括有前途的药物，如GLP-1（胰高血糖素样肽-1）受体激动剂，最初是为2型糖尿病开发的，但现在正在探索更广泛的应用，如心血管疾病和肥胖管理。

The growing focus on addressing obesity and its related conditions underscores the critical need for expert leadership in clinical research – an area in which Vignola's background is invaluable for sponsors with investigational agents..

越来越多的人关注解决肥胖及其相关疾病，这凸显了临床研究中对专家领导力的迫切需求，而维诺拉的背景对于研究机构的赞助商来说是非常宝贵的。。

'Alessandra's deep understanding of the cardiovascular and metabolic markets, combined with her proven track record of leading successful clinical programs, makes her an exceptional addition to our team,' said Dave Bowser, Chief Operating Officer at Worldwide Clinical Trials. 'Her expertise in navigating the complexities of these therapeutic areas, especially with the evolving landscape due to GLP-1 medications on the market, positions Worldwide to remain at the forefront of advancements and continue delivering innovative and high-quality services as we partner with our customers.”.

全球临床试验首席运营官戴夫·鲍瑟（DaveBowser）说：“亚历山德拉（Alessandra）对心血管和代谢市场的深刻理解，加上她在领导成功的临床项目方面的良好记录，使她成为我们团队中的一员。”她在应对这些治疗领域的复杂性方面的专业知识，特别是随着市场上GLP-1药物的不断发展，在全球范围内保持领先地位，并在与客户合作时继续提供创新和高质量的服务。”。

“Today’s cardiovascular and metabolic markets are marked by significant challenges and opportunities. Cardiovascular diseases remain the leading cause of mortality worldwide, while metabolic disorders, including diabetes and obesity, are increasing at an alarming rate,” said Vignola. “The way Worldwide has partnered with its customers for nearly 40 years and the expert teams it has in place are impressive.

维格诺拉说：“今天的心血管和代谢市场面临着巨大的挑战和机遇。心血管疾病仍然是全球死亡的主要原因，而包括糖尿病和肥胖症在内的代谢紊乱正在以惊人的速度增长。”。“The way Worldwide与客户合作近40年，拥有的专家团队令人印象深刻。

I’m happy to join this team and drive more advancements in these areas for patients around the world.”.

我很高兴加入这个团队，为世界各地的患者在这些领域取得更多进步。”。

Vignola’s career began at Bristol-Myers Squibb (BMS), where she developed a strong foundation in the pharmaceutical sector. She then spent a decade at Pfizer, contributing to pivotal clinical research initiatives. Her 15-year tenure at PPD further solidified her expertise across various therapeutic areas, including oncology, hematology, cardiovascular, metabolic, gastrointestinal, liver, and immunology.

维诺拉的职业生涯始于百时美施贵宝（BMS），在那里她在制药行业奠定了坚实的基础。然后，她在辉瑞公司工作了十年，为关键的临床研究计划做出了贡献。她在PPD的15年任期进一步巩固了她在各个治疗领域的专业知识，包括肿瘤学，血液学，心血管，代谢，胃肠道，肝脏和免疫学。

Most recently, Vignola spent three years at Thermo Fisher Scientific, where she was instrumental in driving clinical trial strategies and ensuring operational excellence..

最近，Vignola在Thermo Fisher Scientific工作了三年，在那里她在推动临床试验策略和确保卓越运营方面发挥了重要作用。。

For more information on Worldwide’s experience and capabilities in the cardiovascular and metabolic therapeutic areas, visit www.Worldwide.com.

有关全球在心血管和代谢治疗领域的经验和能力的更多信息，请访问www.Worldwide.com。

About Worldwide Clinical Trials

关于全球临床试验

Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program.

Worldwide Clinical Trials（Worldwide）是一家全方位服务的全球合同研究组织（CRO），与生物技术和制药公司合作，创建定制解决方案，推动新药从发现走向现实。全球范围内的能力包括生物分析实验室服务，I-IV期临床试验，以及批准后和现实世界的证据研究-所有这些都由临床医生，科学家和研究人员组成的无障碍团队提供支持，他们为每个临床项目带来了第一手的专业知识和协作，个性化的方法。

Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com..

世界范围内的治疗重点是神经科学，肿瘤学，罕见疾病以及心脏代谢和炎症性疾病。它的全球足迹跨越近60个国家，拥有3500多名团队成员。。。